naquotinib + midazolam
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small-Cell Lung Cancer (NSCLC)
Conditions
Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations
Trial Timeline
Apr 9, 2014 → Feb 11, 2019
NCT ID
NCT02113813About naquotinib + midazolam
naquotinib + midazolam is a phase 1 stage product being developed by Astellas Pharma for Non-Small-Cell Lung Cancer (NSCLC). The current trial status is completed. This product is registered under clinical trial identifier NCT02113813. Target conditions include Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02113813 | Phase 1 | Completed |
Competing Products
20 competing products in Non-Small-Cell Lung Cancer (NSCLC)